EOCN · Galmed Pharmaceuticals Ltd.
Market Cap
$4.95M
Shares
1.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.48
Open$3.48
Day$3.27–3.92
Available close range$3.41–4.63
Avg vol available · 13d51K
Short vol17%
Last earningsDec 31, 2021
DataAug 2026–Sep 2026
The closing range uses available history since Aug 31, 2026; less than a full year is stored.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
52-week position
6%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Fundamentals
EPS growth
−70%
Y/Y
Free cash flow
$-6.3M
Quant / Vol
risk profile
Volatility
132%
annualized · 1-yr
Max drawdown
−26%
past year
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 18, 2021
Phase 3 R&D budget for the ARMOR program
· for Phase 3
$70M – $80M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its available closing range
Range low $3
Now $3 · 6%
Range high $5
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EOCN
this stock
Galmed Pharmaceuticals Ltd.
|
$4.95M | — | +132.3% | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
14
- % held
- 14.6%
- Net QoQ
- +10.0K sh
- Top holder
- CITADEL ADVISORS LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EOCN | -13.7% | — | — | -15.5% | — |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -14.3% | — | — | -15.0% | — |